“Avacta CEO, Alastair Smith, discusses current trends and advancements in healthcare and highlights how Avacta is well positioned for this medical revolution. Topics covered including genomic sequencing, antibody drug conjugates, stem cells, personalised treatments, immunotherapies.
· Covid rapid lateral flow test (RLFT) – 00:53
· 4 main application areas for AVCT’s 2 platforms – 06:03
· Key Affimer USPs/ functions – 07:28
· Daewoong Pharmaceuticals – 16:03
· Astrea BioSeparations – 23:28
· Biokit – 26:53
· How the RLFT has showcased Affimer technology w/wide – 28:43
· LG Chem – 30:38
· Point Biopharma – 37:18
· ADC Therapeutics – 39:28
· Unique TMAC concept – 42:08
· Moderna – 45:38
· BAMS/Eliza/Bruker – 49:23
· Affimer manufacturing capacity – 52:28”
